These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 18718641

  • 1. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 2. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Oct; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

  • 3. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.
    J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
    [Abstract] [Full Text] [Related]

  • 4. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 5. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R.
    Prostate; 2006 Nov 01; 66(15):1674-85. PubMed ID: 16927304
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 7. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
    Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, Morrill B.
    BJU Int; 2007 Mar 01; 99(3):587-94. PubMed ID: 17407516
    [Abstract] [Full Text] [Related]

  • 8. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

  • 9. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 01; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 10. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
    Bepple JL, Barone BB, Eure G.
    Urology; 2009 Nov 01; 74(5):1101-4. PubMed ID: 19800668
    [Abstract] [Full Text] [Related]

  • 11. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL, Marberger M, Roehrborn CG.
    J Urol; 2006 May 01; 175(5):1657-62. PubMed ID: 16600723
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 01; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 13. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].
    Tsukamoto T, Endo Y, Narita M.
    Hinyokika Kiyo; 2009 Apr 01; 55(4):209-14. PubMed ID: 19462826
    [Abstract] [Full Text] [Related]

  • 14. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS, Roehrborn CG, Wolford E, Wilson TH.
    J Urol; 2007 Apr 01; 177(4):1408-13. PubMed ID: 17382742
    [Abstract] [Full Text] [Related]

  • 15. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M, Ramsdell J, Young J, McNicholas T.
    J Urol; 2006 Sep 01; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [Abstract] [Full Text] [Related]

  • 16. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 17. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
    Hong SK, Min GE, Ha SB, Doo SH, Kang MY, Park HJ, Yoon CY, Jeong SJ, Byun SS, Lee SE.
    BJU Int; 2010 Apr 01; 105(7):970-4. PubMed ID: 19793378
    [Abstract] [Full Text] [Related]

  • 18. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.
    J Clin Endocrinol Metab; 2004 May 01; 89(5):2179-84. PubMed ID: 15126539
    [Abstract] [Full Text] [Related]

  • 19. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb 01; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 20. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.
    Urology; 2005 Jan 01; 65(1):76-82. PubMed ID: 15667867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.